ABBV · News · 20260909N
Guidance / Outlook
AbbVie Inc. · 2026-09-09 · Importance 59 · Surprise 32 · In source text
At a Wells Fargo conference, AbbVie maintained its expectation for high-single-digit annual revenue growth through the decade. Management identified new indications for SKYRIZI and RINVOQ as significant growth drivers and highlighted an expanding oncology and neuroscience pipeline. AbbVie also anticipated a rapid regulatory filing for the cancer therapy etentamig and said increased research and development spending would support innovation.
Key facts
- AbbVie maintains its outlook for high-single-digit annual revenue growth through the decade. source
- AbbVie detailed its strategic approach to business development and increased R&D spending to fuel innovation. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | AbbVie maintains its outlook for high-single-digit annual revenue growth through the decade. |